BCA
ACER

Berman Capital Advisors’s Acer Therapeutics Inc ACER Stock Holding History

Berman Capital Advisors’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,093
Closed -$3K – 1822
2020
Q2 		$3K Sell
1,093
-1,696
-61% -$4.79K ﹤0.01% 1199
2020
Q1 		$5K Hold
2,789
– – ﹤0.01% 912
2019
Q4 		$11K Hold
2,789
– – ﹤0.01% 724
2019
Q3 		$8K Buy
+2,789
New +$8.18K ﹤0.01% 809

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berman Capital Advisors's ACER Position: Q3 2020 in Review

Berman Capital Advisors sold out of Acer Therapeutics Inc (ACER) in Q3 2020, closing a stake of 1,093 shares — an estimated $3K sold.

Berman Capital Advisors first reported a position in ACER in Q3 2019 and held it in 4 quarters. The position peaked at $11K in Q4 2019. 27 funds tracked by Wall St. Rank hold ACER as of Q3 2020.

  • Berman Capital Advisors reported no remaining Acer Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
  • Berman Capital Advisors sold 1,093 Acer Therapeutics Inc shares in Q3 2020, an estimated $3K.
  • Berman Capital Advisors first reported a position in Acer Therapeutics Inc in Q3 2019 and held it in 4 quarters.
  • Berman Capital Advisors's Acer Therapeutics Inc position peaked at $11K in Q4 2019.
  • 27 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q3 2020.

Based on Berman Capital Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.